Litigation Details for Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2021)

✉ Email this page to a colleague

Docket	⤷ Sign Up	Date Filed	2021-06-07
Court	District Court, D. Massachusetts	Date Terminated	2023-11-28
Cause	35:271 Patent Infringement	Assigned To	Allison Dale Burroughs
Jury Demand	Plaintiff	Referred To
Parties	TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Patents	10,392,434
Attorneys	Alissa K. Lipton
Firms	Finnegan, Henderson, Farabow, Garett & Dunner, LLP
Link to Docket	External link to docket

The biologic drug covered by the patent cited in this case is ⤷ Sign Up .

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2021-06-08	1	Complaint	United States patent in the same family as the Patents-in-Suit, U.S. Patent No. 10,392,434 (“the ʼ434 patent…U.S. Patent Nos. 11,028,160 and 11,028,161 (respectively, “the ʼ160 patent” and “the ʼ161 patent”) (together… patent”). On their face, both of the Patents-in-Suit claim priority to the ʼ434 patent. Exs 1, 2. And…in Eli Lilly’s U.S. Patent No. 9,505,838 (“the ʼ838 patent”). Ex. 24 (ʼ838 patent). The amino acid sequences…(together, “the Patents-in- Suit”). The applications that issued as the Patents-in-Suit were assigned	External link to document
2023-11-22	67	Stipulation of Dismissal	United States Patent Nos. 11,028,160 (“the ʼ160 patent”) and 11,028,161 (“the ʼ161 patent”, and together…to the ʼ160 patent, IPR2022-00738; the ʼ161 patent, IPR2022-00739; and United States Patent No. 10,392,434…10,392,434 (“the ʼ434 patent,” and together with the Patents-in-Suit, the “Teva Patents”), IPR2022-00796 … the Teva Patents or any other United States patent, patent application, continuation,…together with the ʼ160 patent, the “Patents- in-Suit”); WHEREAS Lilly filed for inter partes review	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document